• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIA Xuefei, ZHANG Li, LUO Jianhua, YAO Wenbing, GAO Xiangdong, TIAN Hong. Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine[J]. Journal of China Pharmaceutical University, 2021, 52(4): 472-479. DOI: 10.11665/j.issn.1000-5048.20210410
Citation: XIA Xuefei, ZHANG Li, LUO Jianhua, YAO Wenbing, GAO Xiangdong, TIAN Hong. Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine[J]. Journal of China Pharmaceutical University, 2021, 52(4): 472-479. DOI: 10.11665/j.issn.1000-5048.20210410
shu

Design and antitumor activity of immune checkpoint B7-H3 epitope vaccine

  • 1.

    Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009

  • 2.

    The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81973222, No.82073754); Key Research and Development Project of and Xinjiang Autonomous Region (No.2020B03003-2)
More Information
  • Received Date: March 18, 2021
  • Revised Date: June 27, 2021
    Graphical Abstract
    • Abstract
  • B7-H3 is an immune checkpoint molecule overexpressed on the surface of a variety of tumors, and is is an ideal target for tumor immunotherapy. In this study, nitrolated T cell epitope designed in the early stage of the laboratory was used to construct an epitope vaccine that can target immune checkpoint B7-H3. The vaccine can significantly inhibit tumor growth in the CT26 colon cancer model, and has a significant synergistic effect with the PD-L1 protein vaccine. B7-H3 vaccine can increase the proportion of CD4+ T cells in splenic T lymphocytes and the proportion of CD8+ T cells in tumor-infiltrating T lymphocytes, while reducing the proportion of suppressor Treg cells in tumor-infiltrating CD4+ T lymphocytes, which effectively improves tumor immunosuppressive microenvironment. Research results suggest that the B7-H3 epitope vaccine can be used as an effective tumor vaccine candidate molecule.
    • FullText(HTML)
    • References (23)
  • [1]
    . Clin Cancer Res，2016，22（14）：3425-3431.
    [2]
    Kontos F，Michelakos T，Kurokawa T，et al. B7-H3：an attractive target for antibody-based immunotherapy［J］. Clin Cancer Res，2021，27（5）：1227-1235.
    [3]
    Du H，Hirabayashi K，Ahn S，et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells［J］. Cancer Cell，2019，35（2）：221-237.
    [4]
    Leitner J，Klauser C，Pickl WF，et al. B7-H3 is a potent inhibitor of human T-cell activation：no evidence for B7-H3 and TREML2 interaction［J］. Eur J Immunol，2009，39（7）：1754-1764.
    [5]
    Suh WK，Gajewska BU，Okada H，et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses［J］. Nat Immunol，2003，4（9）：899-906.
    [6]
    Kang FB，Wang L，Li D，et al. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression［J］. Oncol Rep，2015，33（1）：274-282.
    [7]
    Mosser DM，Edwards JP. Exploring the full spectrum of macrophage activation［J］. Nat Rev Immunol，2008，8（12）：958-969.
    [8]
    Mao Y，Chen L，Wang F，et al. Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma［J］. Oncol Lett，2017，14（5）：6177-6183.
    [9]
    Castriconi R，Dondero A，Augugliaro R，et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis［J］. Proc Natl Acad Sci U S A，2004，101（34）：12640-12645.
    [10]
    Castellanos JR，Purvis IJ，Labak CM，et al. B7-H3 role in the immune landscape of cancer［J］. Am J Clin Exp Immunol，2017，6（4）：66-75.
    [11]
    Zhang Z，Jiang C，Liu Z，et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors［J］. Mol Ther Oncolytics，2020，17：180-189.
    [12]
    Maeng H，Terabe M，Berzofsky JA. Cancer vaccines：translation from mice to human clinical trials［J］. Curr Opin Immunol，2018，51：111-122.
    [13]
    Wong KK，Li WA，Mooney DJ，et al. Advances in therapeutic cancer vaccines［J］. Adv Immunol，2016，130：191-249.
    [14]
    Tian H，He Y，Song X，et al. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity［J］. Cancer Lett，2018，430：79-87.
    [15]
    Alexander J，Sidney J，Southwood S，et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides［J］. Immunity，1994，1（9）：751-761.
    [16]
    Topalian SL，Drake CG，Pardoll DM. Immune checkpoint blockade：a common denominator approach to cancer therapy［J］. Cancer Cell，2015，27（4）：450-461.
    [17]
    He Y，Tian H，Dai X，et al. Immunogenicity of HER2 vaccine containing p-nitrophenylalanine［J］. J China Pharm Univ（中国药科大学学报） ，2018，49（3）：369-375.
    [18]
    Tian H，Kang Y，Song X，et al. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses［J］. Cancer Lett，2020，476：170-182.
    [19]
    Sharma P，Allison JP. Immune checkpoint targeting in cancer therapy：toward combination strategies with curative potential［J］. Cell，2015，161（2）：205-214.
    [20]
    Mahata B，Pramanik J，Van Der Weyden L，et al. Tumors induce de novo steroid biosynthesis in T cells to evade immunity［J］. Nat Commun，2020，11（1）：3588.
    [21]
    Hendry S，Salgado R，Gevaert T，et al. Assessing tumor-infiltrating lymphocytes in solid tumors：a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group：Part 2：TILs in melanoma，gastrointestinal tract carcinomas，non-small cell lung carcinoma and mesothelioma，endometrial and ovarian carcinomas，squamous cell carcinoma of the head and neck，genitourinary carcinomas，and primary brain tumors［J］. Adv Anat Pathol，2017，24（6）：311-335.
    [22]
    Savage PA，Leventhal DS，Malchow S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells［J］. Immunol Rev，2014，259（1）：245-258.
    [23]
    Stockis J，Roychoudhuri R，Halim TYF. Regulation of regulatory T cells in cancer［J］. Immunology，2019，157（3）：219-231.
    • Related Articles

  • Related Articles

    [1]QIAN Qianqian, LI Guozhi, TIAN Hong, GAO Xiangdong. Design, preparation, and antitumor activity of fusion protein vaccine based on tumor antigen PBK[J]. Journal of China Pharmaceutical University, 2024, 55(5): 657-665. DOI: 10.11665/j.issn.1000-5048.2024030801
    [2]SHAO Shishuai, DUAN Shukang, TIAN Hong, YAO Wenbing, GAO Xiangdong. Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine[J]. Journal of China Pharmaceutical University, 2023, 54(2): 245-254. DOI: 10.11665/j.issn.1000-5048.2023022803
    [3]WU Yaqi, LI Meng, XING Haonan, CHEN Daquan, ZHENG Aiping. Research progress of nasal mucosal immunization vaccine against COVID-19[J]. Journal of China Pharmaceutical University, 2022, 53(6): 643-650. DOI: 10.11665/j.issn.1000-5048.20220602
    [4]ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
    [5]CHEN Wenting, LIU Jun. Advances in research on immune checkpoint and its inhibitors in glioma[J]. Journal of China Pharmaceutical University, 2021, 52(1): 104-112. DOI: 10.11665/j.issn.1000-5048.20210115
    [6]JIANG Liangliang, JIANG Tao, LUO Jianhua, YAO Wenbing, TIAN Hong. A novel human immune system mice model for assessing the immunogenicity of cancer vaccines[J]. Journal of China Pharmaceutical University, 2019, 50(6): 734-742. DOI: 10.11665/j.issn.1000-5048.20190615
    [7]TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
    [8]CHEN Yali, LI Anqi, ZHANG Ningyue, ZHANG Liang. Purification of monoclonal anti-B7-H4 antibody and the blockade of B7-H4-mediated tumor immune evasion by the antibody[J]. Journal of China Pharmaceutical University, 2017, 48(4): 461-468. DOI: 10.11665/j.issn.1000-5048.20170411
    [9]SUN Zhan-yi, CAI Hui, HUANG Zhi-hua, SHI Lei, CHEN Yong-xiang, LI Yan-mei. Advances of glycopeptide-associated tumor vaccines[J]. Journal of China Pharmaceutical University, 2012, 43(2): 97-106.
    [10]Effects of Polysaccharide of Tuber sinica on Tumor and Immune System of Mice[J]. Journal of China Pharmaceutical University, 1994, (5): 289-292.

Catalog

    Get Citation
    PDF
    XML
    Article views (224) PDF downloads (651) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：414732

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return